The Ledger, every show
Every statement that passed quotation and attribution checks, across all 44 shows. Pick shows below, then mix any filter with any other.
shows 
every show 44 of 44
AI outperforms internal human analysts at forecasting Novartis product sales
“The other area, interestingly, in the financial area as well, we find that AI does a great job predicting our free cashflow, predicting a lot of our sales for key products, and it does better than our internal people because it doesn't have the biases and the …”
Viable animal-to-human organ xenotransplantation will arrive within 10 to 20 years
“I think a couple of things will likely come. I think xenotransplantation, I mean, which has been in and out and worked on. And what's interesting is every one of these comes up and down. So, you know, gene therapies, cell therapies popped up in the nineties, k…”
Wearable sensors have failed to meet clinical trial validation standards
“When I think about, first of all, I would say just in general in sensors is another place where there's been a lot of hype Above what, of expectations. I mean, we've been really trying to explore the use of sensors in clinical trials now for, in my own experie…”
Pharma clinical trial success rates have stayed flat at 5 percent
“And actually, when you look at attrition rates in our industry, really the chances of success that we have, they haven't moved in the last 15 years. Still, when we bring a medicine into human beings, on average, only one out of 20 works.”
Novartis will only advance drugs that replace the standard of care
“We internally have just set a very clear bar now for ourselves, primarily because we live in a world now where nobody wants a me too medicine or a medicine that's just incrementally better. We say to ourselves, it has to replace the standard of care.”
Novartis launched first FDA-approved prescription app for opioid addiction
“I mean, one example we launched in the U S a digital medicine. I mean, with paratherapeutics, this is the first digital app with an FDA label that's being used for opioid addiction and other psychiatric illnesses. And it is literally an app That has run clinic…”
Narasimhan: CAR-T therapy development will shift to an iterative model
“I think in the specific example of car T I do think that's, what's going to happen because you have such a complex manufacturing that you're going to have the first generation, let's say of a CD-nineteen card, which is a cart that targets B cell cancers. And y…”
Narasimhan: Scaling technology in clinical trials could cut costs by 20%
“There are estimates now from various sources that believe you could take out 20% of clinical trials costs if you were to actually to really deploy technology at scale.”
Novartis spent $15 billion on gene therapy acquisitions in 2018
“We've done fifteen billion dollars of acquisitions just last year in the space, not, not including all of our internal work in each of these areas.”
Narasimhan: RNA therapies are the only way to drug LP(a)
“And so the only way to really target it turns out to be using RNA based therapies. These RNA based therapies are able to block the production of the gene translation of the gene into the protein and then actually reduce the LP little a in the blood.”
Novartis employs 17,000 R&D staff and spends $9B+ annually
“We have 17,000 R&D people and spend nine, nine billion dollars plus a year in, in R&D.”
The FDA has approved only about 1,500 new molecular entities in history
“Since the creation of the FDA, there's only been about 1500 new molecular entities ever found.”